Who are GFF MDI (PT 003)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vilanterol and Umeclidinium Bromide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gff-mdi-pt-003.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GFF MDI (PT 003) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GFF MDI (PT 003) (GFF MDI (PT 003)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA). Area: Respiratory / Pulmonology.

phase 3 Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) Beta-2 adrenergic receptor; Muscarinic M3 receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

GFF MDI (PT 003) (GFF MDI (PT 003)) — Pearl Therapeutics, Inc.. GFF MDI is a combination inhaled corticosteroid and long-acting beta-2 agonist delivered via metered-dose inhaler for maintenance treatment of asthma and COPD.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GFF MDI (PT 003) TARGET	GFF MDI (PT 003)	Pearl Therapeutics, Inc.	phase 3	Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA)	Beta-2 adrenergic receptor; Muscarinic M3 receptor
Vilanterol and Umeclidinium Bromide	Vilanterol and Umeclidinium Bromide	Samsung Medical Center	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA)	Beta-2 adrenergic receptor; M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) class)

Pearl Therapeutics, Inc. · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GFF MDI (PT 003) — Competitive Intelligence Brief. https://druglandscape.com/ci/gff-mdi-pt-003. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing